Gabriel M. Cohn

Gabriel M. Cohn, M.D., MBA, is the Chief Medical Officer of iECURE. He brings more than 30 years of experience in academic medicine and the biotechnology industry and has contributed to the development of multiple therapeutics for the treatment of rare genetic disorders. Most recently, Dr. Cohn served as the Chief Medical Officer of Homology Medicines where he led the company’s Phase 1/2 gene therapy trial for phenylketonuria (PKU) and supported two investigational new drug (IND) submissions to U.S. Food and Drug Administration (FDA) for the company’s gene editing programs. Previously, he was Vice President of Clinical Development at AVROBIO, leading clinical programs, protocol design, regulatory filings, FDA and Health Canada interactions, and trial site identification and initiations. Dr. Cohn has also served in executive leadership roles at OvaScience and Shire. He is a Fellow of the American College of Genetics Genetics and Genomics (FACMG) and the American College of Obstetrics and Gynecology (ACOG), author of more than 40 peer-reviewed publications, and served as the Chief of Clinical and Reproductive Genetics and Medical Director, Genetic Services at Baystate Medical Center and as Assistant Professor at Tufts University School of Medicine. He earned his M.D. from SUNY Health Science Center at Syracuse and MBA from the Isenberg School of Management at the University of Massachusetts Amherst. He completed a residency in Obstetrics & Gynecology at SUNY HSC at Syracuse and a fellowship in Medical Genetics at the National Institutes of Health.